Scandent Imaging Ltd.
Snapshot View

19.00 +0.30 ▲1.6%

20 May 2022, 04:01:00 PM
Volume: 21,941

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.scandent.in
Market Cap 61.47 Cr.
Enterprise Value(EV) 64.07 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 1.57 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 12.22 Trailing Twelve Months Ending 2021-12
Industry PE 41.03 Trailing Twelve Months Ending 2021-12
Book Value / Share 4.11 Trailing Twelve Months Ending 2021-12
Price to Book Value 4.66 Calculated using Price: 19.15
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 3.21 Cr. 32,100,000 Shares
FaceValue 10
Company Profile

Scandent Imaging is pioneer in providing independent state of the art dental and ENT Imaging solutions. The company provides an exhaustive range of 3D and 2D scan services along with expert reports to cater to the requirements of the dental and ENT fraternity. 

They specialized and intend to provide complete scanning solutions to the growing demands of the dental and ENT fraternity. With the support of renowned and experienced industry professionals and investments into next generation scanning equipments, Scandent offers the best of technology and scanning experience. The company has designed unique imaging packages that match the requirements of the dental and ENT fraternity as well as the affordability of its end users.

Business area of the company:

The company provides dental and ENT Imaging solutions.

Services:

1. Dental:

• 3D Imaging [Cone Beam Computed Tomography]
• 2D Imaging

2. ENT

3. Radiographic reports


Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.60%
1 Week
+0.80%
1 Month
-13.44%
3 Month
-27.89%
6 Month
-5.00%
1 Year
+5.85%
2 Year
+45.82%
5 Year
10 Year
+1627.27%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -1,394.79 0.51 3.92 18.96 0.38 0.57 57.85
Return on Capital Employed (%) 25.57 -2,238.43 -1,096.64 0.58 4.85 25.41 7.15 7.03 44.54
Return on Assets (%) 0.57 -529.42 -1,085.04 0.44 3.13 11.15 0.16 0.18 21.72

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 0 0 4 4 4 5 5 5 9 12
Non Curr. Liab. 0 0 0 6 7 6 4
Curr. Liab. 0 0 1 1 1 5 3 5 5 12
Minority Int.
Equity & Liab. 0 0 5 5 6 10 14 17 20 28
Non Curr. Assets 2 2 3 9 10 11 9 9
Curr. Assets 0 0 3 3 2 0 3 6 11 19
Misc. Exp. not W/O
Total Assets 0 0 5 5 6 10 14 17 20 28

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 0 0 1 2 5 14 13 35 41
Other Income 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 1 2 5 14 13 35 41
Total Expenditure 0 0 0 -1 -2 -4 -13 -11 -27 -32
PBIDT 0 0 0 0 0 2 2 2 8 9
Interest 0 0 0 -1 -1 -1 0
Depreciation 0 0 0 0 -1 -1 -1 -1
Taxation 0 0 0 0 -2 -2
Exceptional Items -25
PAT 0 -25 0 0 1 0 0 4 5
Adjusted EPS -1 -8 0 0 0 0 0 1 2

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 0 3 -3 0 4
Cash Fr. Inv. -2 0 -1 -5 -2 -2 0
Cash Fr. Finan. 0 0 0 5 1 0 5 3 -5
Net Change 0 3 0 0 -2 0 1 -1
Cash & Cash Eqvt 0 3 3 2 0 0 2 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 51.24 51.24 51.24 51.24 51.24 51.24 51.24 51.24 50.73
Public 48.76 48.76 48.76 48.76 48.76 48.76 48.76 48.76 49.27
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 19 May 2022
Board Meeting Intimation for 1St Board Meeting For The Financial Year 22-23
Scandent Imaging Limitedhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve To consider and approve the audited Financial Results for the (Q-4) ended March 31 2022 any other matter with the permission of the board.To consider and approve Increase in Authorised Capital the proposal for various avenues for raising of funds by way of offer and issue of equity shares or any other securities to meet capital requirements of the Company; Subject to and in compliance with the applicable SEBI Guidelines/Orders of the courts and other applicable Acts Rules and Regulations circulars etc; and appoint necessary committees and advisors to execute the same as per statutes.To consider and approve allotment of Equity Shares at fair value to select individuals and companies who have already rendered various services to our company; Subject to and in compliance with the applicable SEBI Guidelines/Orders of the courts and other applicable Acts Rules and Regulations circulars etc; and appoint necessary committees and advisors to execute the same as per statutes.
Tue, 19 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0110
Name of the Signatory :- Pandoo Naig
Designation :- Managing Director / Whole Time Director
Thu, 14 Apr 2022
Regulation 40(9) - PCS Certification
April 13 2022To The Bombay Stock Exchange Limited Department of Corporate Services Phiroze Jeejeebhoy Towers Dalal Street Fort Mumbai 400 001.Scrip Code: 516110Sub: Submission of Certificate pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half financial year ended 31st March 2022.Dear Sir/Madam Please find enclosed herewith Certificate pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half financial year ended 31st March 2022.Kindly take the above documents on your record and acknowledge the receipt.Thanking You Yours faithfully For Scandent Imaging Limited Pandoo NaigManaging DirectorEncl: a/a

Technical Scans View Details

Fri, 20 May 2022
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
Thu, 19 May 2022
Close Crossing Last Month Low Close Crossing Last Month Low
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%